By a News Reporter-Staff News Editor at Gene Therapy Weekly -- New research on Biotechnology is the subject of a report. According to news originating from Salt Lake City, Utah, by NewsRx correspondents, research stated, "Myocardial ischemia needs an alternative treatment such as gene therapy for the direct protection of cardiomyocytes against necrosis or apoptosis and to prevent the development of myocardial fibrosis and cardiac dysfunction. Despite the utility of gene therapy, its therapeutic use is limited due to inadequate transfection in cardiomyocytes and difficulty in directing to ischemic myocardium."
Our news journalists obtained a quote from the research from the University of Utah, "Here, we present a polymeric gene carrier that is capable of targeting ischemic myocardium, resulting in high localization within the ischemic zone of the left ventricle (LV) of an ischemia/reperfusion (I/R) rat model upon systemic administration. Cystamine bisacrylamide-diamino hexane (CD) polymer was modified with the ischemic myocardium-targeted peptide (IMTP) and D-9-arginine (9R) for dual effects of the homing to ischemic myocardium and enhanced transfection efficiency with minimized polymer use. Conjugation of IMTP and 9R to CD led to an increase in transfection under hypoxia and significantly reduced the amount of polymer required for high transfection. Finally, we confirmed targeting of IMTP-CD-9R/DNA polyplex to ischemic myocardium and enhanced gene expression in LV of the I/R rat after tail vein injection."
According to the news editors, the research concluded: "This study provides a clue that gene therapy for the treatment of myocardial ischemia can be achieved by using homing peptide-guided gene delivery systems."
For more information on this research see: Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier. Molecular Pharmaceutics, 2013;10(1):378-85. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
The news correspondents report that additional information may be obtained from Y.W. Won, Center for Controlled Chemical Delivery, Dept. of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, United States. Additional authors for this research include A.N. McGinn, M. Lee, D.A. Bull and S.W Kim (see also technology.html">Biotechnology).
Keywords for this news article include: Utah, Biotechnology, Heart, Ischemia, Treatment, Myocardium, Gene Therapy, United States, Salt Lake City, Bioengineering, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC